<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 11 May 2021 10:14:37 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>首个TSLP抗体申报上市：安进/阿斯利康Tezepelumab</title><link>https://mp.weixin.qq.com/s/qgSwXXoqskJfmSRHsiOA6A</link><description></description><content:encoded><![CDATA[首个TSLP抗体申报上市：安进/阿斯利康Tezepelumab]]></content:encoded><pubDate>Tue, 11 May 2021 09:40:47 +0800</pubDate></item><item><title>AMD：老年黄斑变性</title><link>https://mp.weixin.qq.com/s/zWEHsaJIoDzE-gSmXX0CuA</link><description></description><content:encoded><![CDATA[AMD：老年黄斑变性]]></content:encoded><pubDate>Tue, 11 May 2021 09:40:47 +0800</pubDate></item><item><title>PD-1/CTLA-4双抗为何更有效、更安全？</title><link>https://mp.weixin.qq.com/s/NPuyl-5R6z4U7ygd5XNs3Q</link><description></description><content:encoded><![CDATA[PD-1/CTLA-4双抗为何更有效、更安全？]]></content:encoded><pubDate>Mon, 10 May 2021 17:11:53 +0800</pubDate></item><item><title>博锐生物全面转向大分子新药</title><link>https://mp.weixin.qq.com/s/ftBT3qPFshyibsu43F9Eow</link><description></description><content:encoded><![CDATA[博锐生物全面转向大分子新药]]></content:encoded><pubDate>Mon, 10 May 2021 17:11:53 +0800</pubDate></item><item><title>吉凯基因技术全梳理</title><link>https://mp.weixin.qq.com/s/J5tEbr2DkMqQSCmDYmLJkA</link><description></description><content:encoded><![CDATA[吉凯基因技术全梳理]]></content:encoded><pubDate>Sat, 08 May 2021 07:13:27 +0800</pubDate></item><item><title>首次扭亏为盈：百济神州2021Q1营收39亿元，净利润4.3亿元</title><link>https://mp.weixin.qq.com/s/RygbNCiV1yVgr_u7QzygmQ</link><description></description><content:encoded><![CDATA[首次扭亏为盈：百济神州2021Q1营收39亿元，净利润4.3亿元]]></content:encoded><pubDate>Fri, 07 May 2021 09:00:56 +0800</pubDate></item><item><title>Nature：FDA批准第100款抗体药</title><link>https://mp.weixin.qq.com/s/cBXzVuKbH5hJGyyXccu3yA</link><description></description><content:encoded><![CDATA[Nature：FDA批准第100款抗体药]]></content:encoded><pubDate>Fri, 07 May 2021 09:00:56 +0800</pubDate></item><item><title>补体药物：眼科治疗的重要方向</title><link>https://mp.weixin.qq.com/s/cabQVtUsV3bx0pDT2E407A</link><description></description><content:encoded><![CDATA[补体药物：眼科治疗的重要方向]]></content:encoded><pubDate>Thu, 06 May 2021 09:18:19 +0800</pubDate></item><item><title>默沙东PD-1+HER2获批一线治疗胃癌，信达生物、上海药物所、塞恩塔生物在研PD-1/HER2双抗</title><link>https://mp.weixin.qq.com/s/DClM6vTbfL8mH9eh2iAKnQ</link><description></description><content:encoded><![CDATA[默沙东PD-1+HER2获批一线治疗胃癌，信达生物、上海药物所、塞恩塔生物在研PD-1/HER2双抗]]></content:encoded><pubDate>Thu, 06 May 2021 09:18:19 +0800</pubDate></item><item><title>NDC：上海药物所/深圳大学研发PD-L1纳米抗体偶联药物</title><link>https://mp.weixin.qq.com/s/9jofVHfNOkrkRCYTDix4GQ</link><description></description><content:encoded><![CDATA[NDC：上海药物所/深圳大学研发PD-L1纳米抗体偶联药物]]></content:encoded><pubDate>Wed, 05 May 2021 13:32:29 +0800</pubDate></item><item><title>药明康德研发PD-L1小分子抑制剂</title><link>https://mp.weixin.qq.com/s/zIIWhcPsCtAzIsicZBMfbQ</link><description></description><content:encoded><![CDATA[药明康德研发PD-L1小分子抑制剂]]></content:encoded><pubDate>Wed, 05 May 2021 13:32:29 +0800</pubDate></item><item><title>辉瑞新冠疫苗Q1销售35亿美元，预计全年超260亿美元</title><link>https://mp.weixin.qq.com/s/xDqyC1JEvmPy5zIMUpIsIg</link><description></description><content:encoded><![CDATA[辉瑞新冠疫苗Q1销售35亿美元，预计全年超260亿美元]]></content:encoded><pubDate>Tue, 04 May 2021 20:34:17 +0800</pubDate></item><item><title>国内Th17通路研发格局</title><link>https://mp.weixin.qq.com/s/UQRDONbar3DsnmJPfCXsDA</link><description></description><content:encoded><![CDATA[国内Th17通路研发格局]]></content:encoded><pubDate>Mon, 03 May 2021 08:26:38 +0800</pubDate></item><item><title>2021年一季度全球畅销药TOP10</title><link>https://mp.weixin.qq.com/s/GnobvT20Z4gN52MCBd2LtA</link><description></description><content:encoded><![CDATA[2021年一季度全球畅销药TOP10]]></content:encoded><pubDate>Sat, 01 May 2021 07:20:59 +0800</pubDate></item><item><title>奕拓医药：聚焦不可成药靶标</title><link>https://mp.weixin.qq.com/s/Qx2i2VzhDwFGFDDIKrj7VA</link><description></description><content:encoded><![CDATA[奕拓医药：聚焦不可成药靶标]]></content:encoded><pubDate>Sat, 01 May 2021 07:20:59 +0800</pubDate></item><item><title>弈拓医药：聚焦不可成药靶标</title><link>https://mp.weixin.qq.com/s/AAzSur0Ues6ThVmPOzlhFA</link><description></description><content:encoded><![CDATA[弈拓医药：聚焦不可成药靶标]]></content:encoded><pubDate>Fri, 30 Apr 2021 15:51:42 +0800</pubDate></item><item><title>信达生物申报大分子新药：IBI360</title><link>https://mp.weixin.qq.com/s/awGYxHUNjWkvklEn-Qx8Mg</link><description></description><content:encoded><![CDATA[信达生物申报大分子新药：IBI360]]></content:encoded><pubDate>Fri, 30 Apr 2021 15:51:42 +0800</pubDate></item></channel></rss>